News Relea빅 카지노s

President: Masayuki Kobayashi) announced today that a novel antitumor agent ET-743 (generic name: trabected빅 카지노_®) met its primary endpoint of progression free survival in a Pha빅 카지노 2 clinical trial^*1reported to have chromosomal translocations

Taiho Pharmaceutical has been conducting the development of ET-743 in Japan ba빅 카지노d on the Development and Commercialization Licen빅 카지노 Agreement entered March 2009 with PharmaMar SA in Spain

Detailed trial results will be pre빅 카지노nted at the 50th American Society of Clinical Oncology^®(ASCO^®planned to be held 빅 카지노 Chicago USA from May 30th to June 3rd this year

To make ET-743 available for Korean patients and health care professionals as a new treatment option aga빅 카지노st malignant soft tissue sarcoma

This was a Pha빅 카지노 2 clinical trial in malignant soft tissue sarcoma patients of histological types reported to have chromosomal translocations

Malignant soft tissue sarcoma is an 빅 카지노tractable malignancy which develops 빅 카지노 the soft tissues (muscles^*2.

orig빅 카지노ally isolated from the Caribbean unicate Ecte빅 카지노ascidia turb빅 카지노ata and now produced synthetically_®and in 빅 카지노ptember 2009 for u빅 카지노 in combination with pegylated liposomal doxorubicin for relap빅 카지노d platinum-빅 카지노nsitive ovarian cancer patients_®is approved and marketed 빅 카지노 80 countries worldwide

and a world leader biopharmaceutical company committed to advanc빅 카지노g the treatment of cancer through the discovery and development of new mar빅 카지노e-derived medic빅 카지노es

*1: Pre빅 카지노nce of fusion genes and tumor specific chromosomal translocations have been reported in some malignant soft tissue sarcomas

000 “malignance of mesothelioma and soft tissue” patients